FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2317503308> ?p ?o ?g. }

• W2317503308 abstract "Event Abstract Back to Event Methotrexate mitgates UHMWPE-induced inflammatory osteolysis in murine calvaria model, more than anti-TNF or anti-IL-1R treatments: Implications for extending implant lifetimes Lauryn A. Samelko1, 2, Kyron Mcallister1, Joshua J. Jacobs1 and Nadim Hallab1, 2 1 Rush University, Dept of Orthopedic Surgery, United States 2 Rush University, Dept of Immunology, United States Wear-debris induced osteolysis has been recognized as the primary cause of long term total joint replacement (TJR) failure[1]-[3]. To date, it remains unclear what the most effective strategy for treatment of debris induced periprosthetic osteolysis, with no drugs currently approved for use. Potent anti-inflammatory drugs such as anti-TNF-α, IL-1Ra (Anakinra), and methotrexate (MTX) are used to treat rheumatoid arthritis (RA) and show promise for use in treatment of periprothestic osteolysis, but have yet to be comparatively analyzed and thoroughly investigated. Basic questions remain, such as which drug is more effective and what is the most effective delivery method (local or systemic)? We hypothesize that local administration of MTX will reduce UHMWPE induced-inflammatory osteolysis more than systemic MTX, local anti-TNFa or anti-IL1R, due the pleiotropic anti-inflammatory effects of MTX. To test this, we used an established in vivo murine model of particle-induced osteolysis using UHMWPE particles and subsequently evaluated the degree of particle-induced osteolysis between the different regimens that either received local administration of: (1) sham surgery (did not receive UHMWPE nor biologic treatment; negative control), (2) PBS (positive control), (3) anti-mTNF-α, (4) anti-mIL-1R and (5) MTX (local) and compared that to weekly systemic administration of (6) MTX (systemic), where this latter method has been previously demonstrated to reduce particle induced osteolysis[4]. The greatest and most significant (p<0.02) amount of quantifiable osteolysis in the murine model was observed in the positive control group that received UHMWPE particles +PBS, with 32.5% of bone resorption (Fig. 1b). In contrast, local daily administration of either MTX (10.12% Osteolysis) or anti-mIL-1R (11.59% Osteolysis) to murine calvaria that also received UHMWPE particles, did not significantly increase osteolysis compared to the sham-negative control group (6.23% Osteolysis) (Fig. 1c,e,g). While local anti-mTNF-α (18.54%) administration did not significantly decrease the percentage of osteolysis to sham group but was significantly less compared to the UHMWPE particle +PBS treatment, as well as MTX and anti-mIL-1R treatment group at p<0.02 (Fig. 1d,g). However, there was no statistical significance between osteolysis of anti-mTNF-α and anti-mIL-1R group. The local MTX treatment group had significantly less bone resorption though in comparison to anti-mTNF-α (p=0.05) but not to anti-mIL-1R group. Moreover, systemic administration of MTX was not effective, for the amount of osteolysis is similar to UHMWPE group that did not receive any drug agent, and had significantly more bone resorption compared to local MTX treatment (p=0.008; Fig. 1c,f,h). Our results support our hypothesis that daily local administration of MTX will mitigate UHMWPE-induced inflammatory osteolysis the greatest compared to both local treatment of anti-mTNF-α and anti-mIL-1R or systemic MTX. Local MTX demonstrated to be the most preventive treatment of osteolysis, with bone resorption at only 10.12% and therefore most comparable to that of sham group at 6.23%. More importantly, MTX was more protective given locally as opposed to systemically (p=0.008). Therefore, based on these results, local MTX demonstrates superior promise for use in countering wear-debris induced osteolysis and aseptic loosening. NIH/NIAMS: AR060782.References:[1] Fender D., et al, J Bone Joint Surg Br. 1999;81:577-581.[2] Callaghan JJ., et al, J Bone Joint Surg Am. 1998;80:704-714.[3] Kim YH., et al, J Arthroplasty. 1999;14:538-548.[4] Mediero, A., et al. Arth Rheum, 2015;67:849-855 Keywords: joint replacement, Biocompatibility, Cell response, Implant wear Conference: 10th World Biomaterials Congress, Montréal, Canada, 17 May - 22 May, 2016. Presentation Type: General Session Oral Topic: Biomaterials in immune response Citation: Samelko LA, Mcallister K, Jacobs JJ and Hallab N (2016). Methotrexate mitgates UHMWPE-induced inflammatory osteolysis in murine calvaria model, more than anti-TNF or anti-IL-1R treatments: Implications for extending implant lifetimes. Front. Bioeng. Biotechnol. Conference Abstract: 10th World Biomaterials Congress. doi: 10.3389/conf.FBIOE.2016.01.02526 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 27 Mar 2016; Published Online: 30 Mar 2016. Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Lauryn A Samelko Kyron Mcallister Joshua J Jacobs Nadim Hallab Google Lauryn A Samelko Kyron Mcallister Joshua J Jacobs Nadim Hallab Google Scholar Lauryn A Samelko Kyron Mcallister Joshua J Jacobs Nadim Hallab PubMed Lauryn A Samelko Kyron Mcallister Joshua J Jacobs Nadim Hallab Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page." @default.
• W2317503308 created "2016-06-24" @default.
• W2317503308 creator A5000704253 @default.
• W2317503308 creator A5009119126 @default.
• W2317503308 creator A5028897579 @default.
• W2317503308 creator A5059095037 @default.
• W2317503308 date "2016-01-01" @default.
• W2317503308 modified "2023-09-27" @default.
• W2317503308 title "Methotrexate mitgates UHMWPE-induced inflammatory osteolysis in murine calvaria model, more than anti-TNF or anti-IL-1R treatments: Implications for extending implant lifetimes" @default.
• W2317503308 doi "https://doi.org/10.3389/conf.fbioe.2016.01.02526" @default.
• W2317503308 hasPublicationYear "2016" @default.
• W2317503308 type Work @default.
• W2317503308 sameAs 2317503308 @default.
• W2317503308 citedByCount "0" @default.
• W2317503308 crossrefType "journal-article" @default.
• W2317503308 hasAuthorship W2317503308A5000704253 @default.
• W2317503308 hasAuthorship W2317503308A5009119126 @default.
• W2317503308 hasAuthorship W2317503308A5028897579 @default.
• W2317503308 hasAuthorship W2317503308A5059095037 @default.
• W2317503308 hasBestOaLocation W23175033081 @default.
• W2317503308 hasConcept C126322002 @default.
• W2317503308 hasConcept C141071460 @default.
• W2317503308 hasConcept C150903083 @default.
• W2317503308 hasConcept C17991360 @default.
• W2317503308 hasConcept C185592680 @default.
• W2317503308 hasConcept C202751555 @default.
• W2317503308 hasConcept C207001950 @default.
• W2317503308 hasConcept C2777575956 @default.
• W2317503308 hasConcept C2779918246 @default.
• W2317503308 hasConcept C2781059491 @default.
• W2317503308 hasConcept C2781282405 @default.
• W2317503308 hasConcept C2781411149 @default.
• W2317503308 hasConcept C55493867 @default.
• W2317503308 hasConcept C71924100 @default.
• W2317503308 hasConcept C86803240 @default.
• W2317503308 hasConcept C98274493 @default.
• W2317503308 hasConceptScore W2317503308C126322002 @default.
• W2317503308 hasConceptScore W2317503308C141071460 @default.
• W2317503308 hasConceptScore W2317503308C150903083 @default.
• W2317503308 hasConceptScore W2317503308C17991360 @default.
• W2317503308 hasConceptScore W2317503308C185592680 @default.
• W2317503308 hasConceptScore W2317503308C202751555 @default.
• W2317503308 hasConceptScore W2317503308C207001950 @default.
• W2317503308 hasConceptScore W2317503308C2777575956 @default.
• W2317503308 hasConceptScore W2317503308C2779918246 @default.
• W2317503308 hasConceptScore W2317503308C2781059491 @default.
• W2317503308 hasConceptScore W2317503308C2781282405 @default.
• W2317503308 hasConceptScore W2317503308C2781411149 @default.
• W2317503308 hasConceptScore W2317503308C55493867 @default.
• W2317503308 hasConceptScore W2317503308C71924100 @default.
• W2317503308 hasConceptScore W2317503308C86803240 @default.
• W2317503308 hasConceptScore W2317503308C98274493 @default.
• W2317503308 hasLocation W23175033081 @default.
• W2317503308 hasOpenAccess W2317503308 @default.
• W2317503308 hasPrimaryLocation W23175033081 @default.
• W2317503308 hasRelatedWork W1647631370 @default.
• W2317503308 hasRelatedWork W1977601919 @default.
• W2317503308 hasRelatedWork W2072595400 @default.
• W2317503308 hasRelatedWork W2302120970 @default.
• W2317503308 hasRelatedWork W2314052274 @default.
• W2317503308 hasRelatedWork W2315675502 @default.
• W2317503308 hasRelatedWork W2399149862 @default.
• W2317503308 hasRelatedWork W2594196697 @default.
• W2317503308 hasRelatedWork W2795943328 @default.
• W2317503308 hasRelatedWork W2993533100 @default.
• W2317503308 hasVolume "4" @default.
• W2317503308 isParatext "false" @default.
• W2317503308 isRetracted "false" @default.
• W2317503308 magId "2317503308" @default.
• W2317503308 workType "article" @default.